MX2017000366A - Terapia de combinacion para el cancer. - Google Patents

Terapia de combinacion para el cancer.

Info

Publication number
MX2017000366A
MX2017000366A MX2017000366A MX2017000366A MX2017000366A MX 2017000366 A MX2017000366 A MX 2017000366A MX 2017000366 A MX2017000366 A MX 2017000366A MX 2017000366 A MX2017000366 A MX 2017000366A MX 2017000366 A MX2017000366 A MX 2017000366A
Authority
MX
Mexico
Prior art keywords
cancer
combination therapy
solvate
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2017000366A
Other languages
English (en)
Inventor
Gandhi Anita
Chopra Rajesh
POURDEHNAD Michael
Takeshita Kenichi
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2017000366A publication Critical patent/MX2017000366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan en la presente métodos para tratar, prevenir y/o manejar linfomas y leucemias administrando a un paciente el Compuesto A (3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidi n-2,6-diona), o una sal, solvato o estereoisómero farmacéuticamente aceptable del mismo en combinación con un anticuerpo anti-CD20 o ibrutinib, o una sal o solvato farmacéuticamente aceptable del mismo.
MX2017000366A 2014-07-11 2015-07-10 Terapia de combinacion para el cancer. MX2017000366A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462023748P 2014-07-11 2014-07-11
US201462033062P 2014-08-04 2014-08-04
US201462033566P 2014-08-05 2014-08-05
US201562149941P 2015-04-20 2015-04-20
US201562156928P 2015-05-05 2015-05-05
PCT/US2015/039939 WO2016007854A1 (en) 2014-07-11 2015-07-10 Combination therapy for cancer

Publications (1)

Publication Number Publication Date
MX2017000366A true MX2017000366A (es) 2017-04-27

Family

ID=53682893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000366A MX2017000366A (es) 2014-07-11 2015-07-10 Terapia de combinacion para el cancer.

Country Status (16)

Country Link
US (1) US20170128448A1 (es)
EP (1) EP3166635A1 (es)
JP (1) JP2017521396A (es)
KR (1) KR20170029565A (es)
CN (1) CN107073122A (es)
AU (1) AU2015287694A1 (es)
BR (1) BR112017000556A2 (es)
CA (1) CA2954652A1 (es)
CL (1) CL2017000050A1 (es)
EA (1) EA201790164A1 (es)
HK (1) HK1231381A1 (es)
IL (1) IL249898A0 (es)
MX (1) MX2017000366A (es)
SG (1) SG11201700201UA (es)
WO (1) WO2016007854A1 (es)
ZA (1) ZA201608559B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2420498T (lt) 2006-09-26 2017-10-25 Celgene Corporation 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
EA026100B1 (ru) 2011-03-11 2017-03-31 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
WO2014039421A1 (en) 2012-09-04 2014-03-13 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
BR112018010964A2 (pt) 2015-12-02 2018-12-04 Celgene Corp terapia de ciclo usando 3-(5-amino-2-methil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
AU2018355145A1 (en) * 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
CA3154066A1 (en) * 2019-10-08 2021-04-15 Uab Research Foundation Combination therapy with glucarpidase with methotrexate/rituximab to treat cns lymphoma
AU2020370039B2 (en) * 2019-10-21 2026-02-19 Celgene Corporation Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same
CA3154510A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
WO2023144290A1 (en) * 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024108028A1 (en) * 2022-11-16 2024-05-23 Salarius Pharmaceuticals, Inc. Methods of use of deuterium-enriched compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6480162B2 (en) * 2000-01-12 2002-11-12 Emag Technologies, Llc Low cost compact omini-directional printed antenna
US7346839B2 (en) * 2003-09-30 2008-03-18 Google Inc. Information retrieval based on historical data
US20060003059A1 (en) * 2004-07-02 2006-01-05 Burt Tabora Combined preparation and apparatus for use with a food blender and method for making preparation
TWI423039B (zh) * 2010-07-23 2014-01-11 Quanta Comp Inc 伺服器系統與其操作方法
PT2683384E (pt) * 2011-03-11 2016-03-11 Celgene Corp Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
AU2014254056B2 (en) * 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
MX368286B (es) * 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
CN105339008A (zh) * 2013-04-17 2016-02-17 西格诺药品有限公司 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
WO2014179661A1 (en) * 2013-05-03 2014-11-06 Celgene Corporation Methods for treating cancer using combination therapy

Also Published As

Publication number Publication date
KR20170029565A (ko) 2017-03-15
AU2015287694A1 (en) 2017-02-02
CA2954652A1 (en) 2016-01-14
HK1231381A1 (zh) 2017-12-22
CL2017000050A1 (es) 2017-08-11
JP2017521396A (ja) 2017-08-03
ZA201608559B (en) 2018-04-25
BR112017000556A2 (pt) 2017-11-07
IL249898A0 (en) 2017-03-30
CN107073122A (zh) 2017-08-18
EA201790164A1 (ru) 2017-10-31
WO2016007854A1 (en) 2016-01-14
SG11201700201UA (en) 2017-02-27
US20170128448A1 (en) 2017-05-11
EP3166635A1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
MX2017000366A (es) Terapia de combinacion para el cancer.
MY186977A (en) Tetrasubstituted alkene compounds and their use
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
EA201790398A1 (ru) Способы лечения заболевания печени
PH12018502731A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12017500933A1 (en) Sublingual administration of riluzole
MX382754B (es) Terapias combinadas para tratar el cancer.
PH12017500934A1 (en) Sublingual formulation of riluzole
SA515370011B1 (ar) طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين
CL2018001434A1 (es) Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
MA39599A (fr) Dosage et administration d'agents thérapeutiques anti-egfr
MX2016011706A (es) Formulaciones de progesterona.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
IN2014DE00818A (es)
IN2014DE00822A (es)
UA82641U (ru) Способ лечения нейросифилиса с паренхиматозными изменениями
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
UA88769U (uk) Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності
UA86338U (ru) Способ лечения беременных с гестационным диабетом
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA92214U (ru) Способ лечения диабетической полиневропатии у больных сахарным диабетом 2-го типа
UA91788U (uk) Спосіб інтра- та післяопераційного введення гепатопротекторів при вогнищевих ураженнях печінки